Other Events ·
Regains Nasdaq compliance with $1.00 minimum bid price; reports preliminary Q3 revenue of $1.22M
SCNXScienture Holdings, Inc.
Nasdaq notified Scienture Holdings that its common stock closed at or above $1.00 per share for ten consecutive trading days between October 5 and October 16, 2026, confirming the company has regained compliance with the Minimum Bid Price Requirement. Consequently, Nasdaq determined the delisting matter is closed and securities will remain listed. Separately, the company announced preliminary, unaudited revenue of approximately $1.22 million for the third quarter ended September 30, 2026, a 256% increase from the prior quarter's $344,000, driven by the commercial launch of REZENOPY and continued sales growth of Arbli. Scienture Holdings is a specialty pharmaceutical company focused on developing and commercializing novel products.